CytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $25.11 million versus the consensus estimate of $20 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.